Children with heart defects are often given adapted versions of devices and drugs made for adults, putting them at risk for complications and medical errors. The number of children who need these interventions is too small to make it financially feasible for companies to develop pediatric versions of angioplasty balloons and other devices. However, the FDA recently approved a heart valve for pediatric use, and clinical trials are under way to compare different surgical approaches and drug regimens for children with congenital heart defects.

Related Summaries